Latest From Indivior PLC
US FDA might approve Indivior and Braeburn's injectable buprenorphine products simultaneously; here's a side-by-side look at the advantages and disadvantages of each.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.
US FDA advisory committee had dosing and dispensing concerns about both buprenorphine injectable products, but each ended up with a strong vote in favor, clearly benefiting from public health attention to opioid addiction and the call for broader access to treatment.
Seventeen of the panelists voted that the clinical data support approval for some of Braeburns proposed doses, but no one supported the highest proposed monthly dose.
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- Reckitt Benckiser Pharmaceuticals Inc.
- Western Europe
- Company Type
- Parent & Subsidiaries
- Indivior PLC
- Senior Management
Shaun Thaxter, CEO
Cary Claiborne, CFO
Tim Baxter, MD, CMO
Tony Goodman, Chief Bus. Dev. Officer
Christian Heidbreder, PhD, CSO
Richard Simkin, Chief Commercial Officer
- Contact Info
Phone: (0)1753 217800
215 Bath Rd.
Slough, SL1 4AA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.